714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

L.S. Chan, Mikiko Kudo, Bruno Sangro, R. K. Kelley, Junji Furuse, Jung‐Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Ann‐Lii Cheng, Sérgio Jobim Azevedo, M.E. Reig Monzon, Éric Assenat, Mark Yarchoan, Aiwu Ruth He, M. Makowsky, D. Ran, Alejandra Negro, G.K. Abou-Alfa